litigation trends

Subscribe to litigation trends via RSS

According to the latest annual report from ISS Securities Class Action Services, there were two securities class action settlements in 2021 that were large enough to make the firm’s list of the Top 100 U.S. Securities Class Action settlements. These two settlements took place in a year in which there were a total of 116 approved monetary securities class action settlements totaling $3.51 billion. The details of the settlements included the two largest during 2021 can be found in the ISS SCAS report entitled “The Top 100 U.S. Class Action Settlements of All-Time,” here.
Continue Reading ISS Releases 2021 Top 100 Securities Class Action Lawsuit Settlements List

As reflected in their January 18, 2022 stipulation of settlement, the parties to the consolidated Teva Pharmaceutical Industries securities class action litigation have reached an agreement to settle the case for a payment of $420 million. The settled claims relate to underlying allegations concerning price-fixing in connection with the company’s generic drug products. According to the statements of a company spokesperson, the “vast majority” of the settlement amount will be funded by the company’s D&O insurers. The settlement is subject to court approval. A copy of the parties’ January 18, 2022 stipulation of settlement can be found here.
Continue Reading Teva Settles Price-Fixing-Related Securities Class Action Litigation for $420 Million

In the latest COVID-related securities class action lawsuit, a shareholder plaintiff has filed a securities suit against a clinical-stage pharmaceutical company whose application for emergency use authorization (EUA) for a COVID-19-related treatment therapy was rejected by the FDA. Among other things, this latest filing shows that the wave of coronavirus-related securities lawsuit filings, like the coronavirus itself, show few signs of abatement. A copy of complaint filed on January 18, 2022 against NRx Pharmaceuticals can be found here.
Continue Reading COVID-19-Related Securities Suit Filed Against Pharma Company

Sarah Abrams
Bret Hilgart

Corporate share repurchases hit record levels in 2021. But as discussed in the following guest post by Sarah Abrams and Bret Hilgart, share repurchases can sometimes result in litigation and share repurchases could have important implications for directors and officers’ liability. Sarah is Head of Professional Liability at Bowhead Specialty Underwriters and Bret is Head of Commercial D&O at Bowhead Specialty Underwriters. I would like to thank Sarah and Bret for allowing me to publish their article as a guest post on this site. I welcome guest posts from responsible authors on topics of interest to this blog’s readers. Please contact me directly if you would like to submit a guest post. Here is Sarah and Bret’s article.
Continue Reading Guest Post: Scrutiny Over Share Repurchase Programs; Can The Board Ever Get It Right?

As I noted in my recent round-up of the Top Ten D&O Stories of 2021, one of last year’s important securities litigation stories was the onslaught during the year of SPAC-related securities class action lawsuit filings. I also added in the year-end round-up my projection that SPAC-related securities suits could be an even bigger factor in 2022. Though we are only in the opening days of 2022, the filing of SPAC-related securities suits in the New Year has already begun. On January 7, 2022, a shareholder plaintiff filed the first SPAC-related securities suit of 2022 against the post-merger company and certain of its officers, as well as against former officers and directors of the SPAC itself and its Sponsor. A copy of the complaint filed against Talkspace, Inc. can be found here.
Continue Reading First SPAC-Related Securities Suit of the New Year Filed

As I have noted on this site, even though it has now been nearly 22 months since the initial coronavirus outbreak in the U.S., coronavirus D&O lawsuits have continued to be filed continuously since the initial outbreak. Coronavirus-related securities suits were in fact a significant securities litigation phenomenon in 2021 as well as in 2020. In an early sign that the coronavirus related litigation could remain a significant securities litigation factor in 2022, late last week plaintiffs’ lawyers filed two new securities lawsuits against a health insurance and services company and against a diagnostic testing company. Both companies had completed IPOs earlier in 2021. A copy of the new securities lawsuit against Bright Health Group can be found here and a copy of the new securities suit against Talis Biomedical Corporation can be found here.
Continue Reading First Coronavirus-Related Securities Suits of 2022 Filed

The directors’ and officers’ liability environment is always changing, but 2021 was a particularly eventful year, with important consequences for the D&O insurance marketplace. The past year’s many developments also have significant implications for what may lie ahead in 2022 – and possibly for years to come.  I have set out below the Top Ten D&O Stories of 2021, with a focus on the future implications. Please note that on Thursday, January 13, 2022 at 11:00 AM EST, my colleague Marissa Streckfus and I will be conducting a free, hour-long webinar in which we will discuss The Top Ten D&O Stories of 2021. Registration for the webinar can be found here. I hope you will please join us for the webinar.
Continue Reading The Top Ten D&O Stories of 2021

The number of federal court securities class action lawsuits filed during 2021 declined significantly compared to the number filed in 2020, and the number of 2021 filings was sharply below the elevated number of securities suits filed each year during the period 2017-2019. The most significant factor in the 2021 drop-off was the decline in the number of federal court merger objection class action lawsuit filings during the year, although there were other factors at work as well. Though the number of filings in 2021 declined relative to the elevated number of annual filings during period 2017-2020, the number of 2021 filings was above longer-term historical annual filings levels prior to 2017, as discussed below.
Continue Reading Securities Filings Declined in 2021 Relative to Recent Elevated Years, Closer to Long-Term Levels

As long-time readers of this blog know, one of the long-range concerns in the D&O insurance industry is the possible exposures of corporate directors and officers to liability claims arising from climate change (as discussed most recently here). In the following guest post, attorneys from the Legalign Global Alliance member firms take a comprehensive look at the climate change-related risks and exposure that corporate directors and officers may face, as well as at the climate change-related D&O claims developments in a variety of different countries. A version of this article previously was published as a Legalign Global client alert. I would like to thank the authors for allowing me to publish their article as a guest post on this site. I welcome guest post submissions from responsible authors on topics of interest to this blog’s readers. Please contact me directly if you would like to submit a guest post. Here is the authors’ article.
Continue Reading Guest Post: D&O Exposures to Climate Change Risk

As I have noted on this site (most recently here), electric vehicle companies that have merged with publicly traded SPACs have become a favored target for plaintiffs’ securities lawyers. In the latest example of this phenomenon, on December 23, 2021, a plaintiff shareholder filed a securities class action lawsuit against the EV company Faraday Future Intelligent Electric, Inc., which merged with a SPAC on July 21, 2021. Like many of the EV companies that have been sued, Faraday Future’s stock price dropped after it was the subject of a short seller report. A copy of the complaint against Faraday Future can be found here.
Continue Reading And Again: Another Post-SPAC Merger EV Company Hit with Securities Suit